The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.n

ILD with a granulomatous component

Publications

Nishino M, Hatabu H, Sholl LM, Ramaiya NH

Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.

Radiographics : a review publication of the Radiological Society of North America, Inc 2017 Sep-Oct;37;1371-1387 — 2017 Sep-Oct — 1371-1387

Al-Dliw M, Megri M, Shahoub I, Sahay G, Limjoco TI, Shweihat Y

Pembrolizumab reactivates pulmonary granulomatosis.

Respiratory medicine case reports 2017;22;126-129 — 2017 — 126-129

Cousin S, Toulmonde M, Kind M, Cazeau AL, Bechade D, Coindre JM, Italiano A

Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab.

Annals of oncology : official journal of the European Society for Medical Oncology 2016 06;27;1178-9 — 2016 06 — 1178-9